Syngene International has appointed Siddharth Mittal as Managing Director and Chief Executive Officer, effective July 1, with the 13-year Biocon veteran tasked with arresting a significant profit decline at India's largest contract research and development organisation. Mittal, who led Biocon as Chief Financial Officer and subsequently as Managing Director and CEO, succeeds Peter Bains, who completed a tenure marked by expansion in the company's customer base but also periods of operational strain. The appointment marks the second major leadership change at Syngene in 18 months, underscoring board concerns about profitability headwinds.
Kiran Mazumdar-Shaw, Executive Chairperson of Syngene, said she had worked closely with Mittal for many years and observed his ability to lead businesses through periods of change and deliver transformation and sustainable growth. The appointment reflects confidence that Mittal's financial acumen and focus on execution will help Syngene unlock its potential. No search firm involvement was disclosed in the announcement. Mittal commented that his immediate priorities include sharpening commercial edge, strengthening delivery excellence, and bringing greater focus and discipline to execution, positioning these as foundational to restoring growth momentum.
Mittal, who holds a Bachelor of Commerce from Symbiosis College and is a Chartered Accountant from India's ICAI, joined Biocon in May 2013 as Vice President of Finance. He served as President and Chief Financial Officer from August 2014 through November 2019 before being elevated to Managing Director and CEO in December 2019. During his tenure at Biocon, Mittal oversaw the biosimilars business through its strategic spinoff into Biocon Biologics and subsequently led the company's foray into generic formulations. He also played a pivotal role in commercialising Biocon's GLP-1 portfolio across global markets and executing strategic partnerships that strengthened competitive positioning. His leadership style is characterised as data-driven decision-making with an emphasis on partnership-building, and industry observers credit him with creating shareholder value and strengthening commercial operations.
Syngene International is a global contract research, development, and manufacturing organisation employing over 8,300 staff across facilities in India and the United States. Founded in 1994 as a Biocon subsidiary and listed in 2015, Syngene generates revenue from approximately 400 customers across pharmaceutical, biotechnology, nutrition, and specialty chemical sectors, with major clients including Bristol Myers Squibb, GlaxoSmithKline, Zoetis, and Merck KGaA. The company operates over 3 million square feet of specialised facilities for discovery, development, and manufacturing.
The appointment comes after Syngene reported a net profit of Rs 15 crore for Q3 fiscal 2026, an 88.56 percent year-on-year decline reflecting what management attributed to margin compression and inventory corrections related to a large-molecule biologics client. Operating profit margins fell to 22.81 percent from 30.05 percent year-on-year, and full-year profit after tax declined 35.36 percent for the nine months ending March 2026. The company's stock has underperformed Indian equity benchmarks significantly, declining approximately 40 percent over the past year while the Sensex gained modestly. Analysts view Mittal's appointment as potentially beneficial given his financial background and execution focus, though some have expressed concern that his primarily biopharmaceutical experience at Biocon may differ from the contract services model at Syngene. An extended partnership with Bristol Myers Squibb through 2035 provides revenue visibility that should offer some stability as Mittal implements operational improvements.
